Thank you, Omer. Good morning, everyone. Starting with cash. We ended Q3 2023 with approximately $164 million in cash, bank deposits, marketable securities, and short-term restricted cash on the balance sheet. With our cost structure being largely mature, our operating cash outlays remained mostly stable during the quarter on a normalized basis. We did defer roughly $2.9 million of R&D expense as a result of booking NRE revenue. While this drove lower-than-normal operating expenses in the third quarter, we expect to recognize the deferred expenses in the coming quarter as COGS. At a higher level, on a normalized basis, you can see that our cost structure has been mostly flat since the second half of 2022. The bulk of the growth in our cost structure occurred during our transition from a Tier 2 to a Tier 1 relating to the Volkswagen Group award in 2022. As we have said before, with the transition to a Tier 1 mostly behind us, we do not expect material increase in our cost structure. One of the factor behind this flexibility is our transition to SOP with the InnovizOne. As this program transitioned from development stages to high-volume manufacturing, it freed up headcount to work on either the RFQ pipeline or the InnovizTwo SOP. This gives us meaningful flexibility going forward without the need to significant growth in our fixed costs. Moving to the income statement, revenue in Q3 2023 came in at $3.5 million compared to Q2 2023 revenues of $1.5 million, delivering a 138% quarter-over-quarter increase. On a year-over-year basis, it compares to Q3 2022 revenues, which were impacted by our headquarters move of $0.9 million, delivering growth of nearly 300% year over year. On the cost side, operating expenses for Q3 2023 were $27.8 million, a decrease from $31.3 million in Q3 2022. As I mentioned earlier, Q3 2023 operating expenses saw $2.9 million dollars of R&D expenses deferred into future quarters and will be recognized as COGS to match costs with future NRE revenues. This quarter's operating expenses included $5 million of share-based compensation compared to $4.9 million in Q3 2022. Research and development expenses for Q3 2023 were $20.7 million, a decrease from $24.2 million in Q3 2022. The quarter's R&D expenses included $3.1 million attributable to share-based compensation compared to $3.2 million in Q2 2022. In conclusion, we are delivering on the growth cadence that we laid out coming into the year. Q1 2023 was the trough. We delivered a 45% quarter-over-quarter growth in Q2, 138% in Q3, and have line of sight to another meaningful step-up in the fourth quarter. Even more importantly, we are executing on this growth while dealing with record level of RFQ activity. We expect to finish the year on a very strong note with continued momentum for 2024 and beyond. And with that, I will turn the call back to Omer.